

해외 바이오의약품 임상 현황 ('23년 7월 2주)

한국바이오의약품협회, 2023.07.18.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.07.10.~2023.07.16.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 16건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05882734	M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDriver NSCLC 322)	Drug: M1774 Drug: Cemiplimab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05882734
NCT05407441	Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors	Drug: Tazemetostat Drug: Nivolumab Drug: Ipilimumab	Susan Chi, MD Bristol-Myers Squibb Epizyme, Inc. Dana-Farber Cancer Institute	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05407441
NCT05910801	Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Lenalidomide Procedure: Lumbar Puncture Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Biological: Tafasitamab Drug: Venetoclax	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05910801
NCT05892432	Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)	Drug: Semaglutide 3 MG [Rybelsus] Drug: Semaglutide 7 MG [Rybelsus] Drug: Placebo	University of Colorado, Denver National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05892432
NCT05801939	Cevostamab Following CAR T Cell Therapy for RRMM	Drug: Cevostamab	University of Pennsylvania Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05801939
NCT05718869	Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study	Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Biological: Tafasitamab Drug: Zanubrutinib	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718869
NCT05700630	Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia	Biological: FT538 Drug: Vorinostat	Masonic Cancer Center, University of Minnesota	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05700630
NCT05609630	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	Drug: Upadacitinib Drug: Tocilizumab	AbbVie	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05609630
NCT05350774	Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2	Drug: IV normal saline Drug: IV immunoglobulin	National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health Clinical Center (CC)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05350774
NCT05321940	Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias	Biological: STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells Biological: Dendritic Cell Vaccine	Juan C. Ramos, MD University of Miami	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05321940

해외 바이오의약품 임상 현황 ('23년 7월 2주)

한국바이오의약품협회, 2023.07.18.

○ 미국 16건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05916560	A Study of LY3437943 in Participants With Impaired and Normal Liver Function	Drug: LY3437943	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05916560
NCT05925803	Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)	Biological: Anifrolumab (blinded) Drug: Placebo (blinded) Biological: Anifrolumab (unblinded, open label)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05925803
NCT05918250	mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Biological: mRNA-2736	ModernaTX, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05918250
NCT05869955	A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE)	Drug: CC-97540 Drug: Fludarabine Drug: Cyclophosphamide	Bristol-Myers Squibb	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05869955
NCT05626322	Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Drug: Maplirpacept Drug: Tafasitamab Drug: Lenalidomide	Pfizer MorphoSys AG Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05626322
NCT05722938	Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Drug: Trimodulin Drug: Placebo (human albumin 1%)	Biotest	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05722938

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05925803	Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)	Biological: Anifrolumab (blinded) Drug: Placebo (blinded) Biological: Anifrolumab (unblinded, open label)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05925803

○ 프랑스 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05855811	PREventing Second Cancers With DOSTARlimab	Drug: Dostarlimab	Centre Leon Berard GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05855811
NCT05925803	Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)	Biological: Anifrolumab (blinded) Drug: Placebo (blinded) Biological: Anifrolumab (unblinded, open label)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05925803

○ 독일 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05925803	Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)	Biological: Anifrolumab (blinded) Drug: Placebo (blinded) Biological: Anifrolumab (unblinded, open label)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05925803
NCT05869955	A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE)	Drug: CC-97540 Drug: Fludarabine Drug: Cyclophosphamide	Bristol-Myers Squibb	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05869955
NCT05722938	Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Drug: Trimodulin Drug: Placebo (human albumin 1%)	Biotest	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05722938

해외 바이오의약품 임상 현황 ('23년 7월 2주)

한국바이오의약품협회, 2023.07.18.

○ 중국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05904379	AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer	Drug: AK112 Drug: AK104 Drug: caboplatin Drug: paclitaxel Drug: pemetrexed Drug: Docetaxel	Akeso	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05904379&rank=1
NCT05944809	The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients	Drug: rhTPO	JIANYANG WANG Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05944809&rank=1
NCT05939596	A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)	Biological: SARS-CoV-2 Bivalent mRNA Vaccine Other: Saline	AIM Vaccine Co., Ltd. Zhejiang Provincial Center for Disease Control and Prevention	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05939596&rank=1
NCT05939167	Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage	Drug: mesenchymal stem cell Other: saline	Cell Energy Life Sciences Group Co. LTD Beijing 302 Hospital Shenzhen Third People's Hospital Fifth Hospital of Shijiazhuang City Beijing YouAn Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05939167&rank=1
NCT05925452	To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.	Drug: GenaKumab	GeneScience Pharmaceuticals Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05925452&rank=1
NCT05911217	A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer	Drug: CT041 autologous CAR T-cell injection	CARsgen Therapeutics Co., Ltd. Fudan University	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05911217&rank=1
NCT05925803	Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)	Biological: Anifrolumab (blinded) Drug: Placebo (blinded) Biological: Anifrolumab (unblinded, open label)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05925803&rank=1
NCT05948033	CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma	Biological: CD70-targeting CAR-T cells	Chinese PLA General Hospital UTC Therapeutics Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05948033&rank=1
NCT05947487	CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors	Biological: CD70-targeting CAR-T cells	Chinese PLA General Hospital UTC Therapeutics Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05947487&rank=1
NCT05948072	Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM	Drug: mFOLFOX6 + Cetuximab Drug: mFOLFOX 6	Fudan University	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05948072&rank=1

○ 일본 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpcept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.	Drug: maplirpcept (PF-07901801) Drug: Glofitamab Drug: Obinutuzumab	Pfizer Hoffmann-La Roche	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05896163&rank=1
NCT05925803	Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)	Biological: Anifrolumab (blinded) Drug: Placebo (blinded) Biological: Anifrolumab (unblinded, open label)	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05925803&rank=1
NCT05626322	Effects of Maplirpcept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Drug: Maplirpcept Drug: Tafasitamab Drug: Lenalidomide	Pfizer MorphoSys AG Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05626322&rank=1